-
1.
公开(公告)号:US09598423B2
公开(公告)日:2017-03-21
申请号:US15034217
申请日:2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: A61K31/498 , C07D487/04 , C07D491/147 , C07D487/10 , C07D491/20 , C07D487/20 , C07D519/00
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
2.SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS 审中-公开
Title translation: 取代4,5,6,7-四氢吡唑并[1,5-A]吡啶衍生物作为CASEIN KINASE 1 D / E抑制剂公开(公告)号:US20160311824A1
公开(公告)日:2016-10-27
申请号:US15034217
申请日:2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Upender Velaparthi , Chetan Padmakar Dame , Peiying Liu , Mark D Wittman , Bradley C. Pearce , Erika M.V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00 , C07D487/10
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 及其药学上可接受的盐。 式(I)的化合物抑制蛋白激酶活性,从而使它们用作抗癌剂。
-
公开(公告)号:US20160122358A1
公开(公告)日:2016-05-05
申请号:US14994346
申请日:2016-01-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Subbiah Karuppiah , Subba Reddy Bandreddy , Nagalakshmi Pulicharla , Rajesh Onkardas Bora , Shilpa Maheshwarappa Holehatti , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Kumar Sistla
IPC: C07D487/04 , C07D487/20 , C07D491/20 , C07D487/10 , C07D491/147
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
-
4.Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors 有权
Title translation: 取代的吡唑并 - 哌嗪作为酪蛋白激酶1δ/ 抑制剂公开(公告)号:US09273058B2
公开(公告)日:2016-03-01
申请号:US14541343
申请日:2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , A61K31/4985 , A61K31/499 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P19/02
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)的化合物抑制蛋白激酶活性,从而使它们用作抗癌剂。
-
5.NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS 有权
Title translation: 新型替代吡唑并吡啶作为CASEIN KINASE 1 D / E抑制剂公开(公告)号:US20150133428A1
公开(公告)日:2015-05-14
申请号:US14541343
申请日:2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D491/20 , C07D491/147
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式(I)化合物及其药学上可接受的盐。 式(I)的化合物抑制蛋白激酶活性,从而使它们用作抗癌剂。
-
公开(公告)号:US11166959B2
公开(公告)日:2021-11-09
申请号:US16761449
申请日:2018-11-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Erika M. V. Araujo , Yan Chen , Bireshwar Dasgupta , Andrew P. Degnan , Matthew D. Hill , Godwin Kwame Kumi , Harold A. Mastalerz , Mark D. Wittman , Bradley C. Pearce , Guifen Zhang
IPC: A61K31/5377 , A61K31/506 , A61P35/00 , A61K45/06 , C07D405/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/048 , C07D498/10 , C07D519/00
Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CH or N; Y is CR5 or N; and R1, R2, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase 1 (HPK1), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
-
-
-
-